There are hundreds of Covid-19 vaccines in development, with a number now approved and being rolled out around the world. How do some of the different vaccines work and compare?
Covid-19 vaccines explained
Critics warned against the UK policy of leaving a longer gap between doses of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines. Now we have more data, what do we actually know?
Unprecedented international cooperation and focus have led to multiple effective and safe Covid-19 vaccines in less than a year, and created a blueprint for future vaccine development.
How we're supporting research
We’re supporting global vaccine research and development efforts through CEPI, the Coalition for Epidemic Preparedness Innovations.
CEPI has been funding the development of nine Covid-19 vaccines, including Oxford-AstraZeneca and Moderna, with several others in phase III clinical trials.
The first-generation vaccines we currently have were developed to target the original virus, so we need to know how effective they are against new and emerging variants, and how to guide development of the next generation of vaccines. That's why it's vital to carry on investing in research.
Vaccines for everyone
To overcome the pandemic, we have to overcome it everywhere in the world. But we will only succeed if vaccines are available and affordable to all countries.
Here's how governments and international organisations can help make sure that vaccines reach everyone who needs them.
- Invest in the ACT-Accelerator. This global collaboration of health organisations, scientists, businesses, civil society, governments and philanthropies, including Wellcome, is working to get lifesaving tests, treatments and vaccines from the laboratory to the front line. An investment of $16.8 billion is still needed in 2021 to fund this work.
- Donate excess vaccine doses through COVAX. Rich countries that have secured lots of excess vaccine doses must donate these through COVAX, who will ensure that vaccines go where they are needed most.
Coronavirus treatments and vaccines should first be made available to those who need them most, public polling in several countries shows.